{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:orserdu:0:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Aorserdu%3A0%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002184, "timestamp_received": "2026-10-16T23:00:26.155045+00:00Z", "timestamp_returned": "2026-10-16T23:00:26.157229+00:00Z", "trace_id": "6857d1e9-315c-4201-89d6-683db612a588" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:orserdu:0:0", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2023-09-15:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2023-09-15", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:orserdu", "type": "Document", "documentType": "Regulatory approval", "name": "Orserdu (elacestrant) [product information]. EMA.", "title": null, "aliases": [], "description": "Stemline Therapeutics B.V. Orserdu (elacestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Stemline Therapeutics B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Orserdu", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "elacestrant", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2023-11-27", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-02-14", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:110", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C9245", "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Invasive+Breast+Carcinoma+%28BRCA%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C9245", "code": "C9245", "name": "Invasive Breast Carcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C9245" ] } }, "objectTherapeutic": { "id": "tx:ncit:C120211", "conceptType": "Therapy", "name": "Elacestrant", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2628469", "code": "2628469", "name": "elacestrant", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2628469" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1301646", "code": "1301646", "name": "elacestrant", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1301646" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "ER signaling inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C120211", "code": "C120211", "name": "Elacestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C120211" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:1", "present": true, "subject": { "id": "bmkr:1", "type": "CategoricalVariant", "name": "ER positive", "constraints": [], "extensions": [ { "name": "biomarker_type", "value": "Protein expression" }, { "name": "marker", "value": "Estrogen receptor (ER)" }, { "name": "unit", "value": "status" }, { "name": "equality", "value": "=" }, { "name": "value", "value": "Positive" } ] } }, { "id": "bmkr.criterion:2", "present": true, "subject": { "id": "bmkr:2", "type": "CategoricalVariant", "name": "HER2-negative", "constraints": [], "extensions": [ { "name": "biomarker_type", "value": "Protein expression" }, { "name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)" }, { "name": "unit", "value": "status" }, { "name": "equality", "value": "=" }, { "name": "value", "value": "Negative" } ] } }, { "id": "bmkr.criterion:58", "present": true, "subject": { "id": "bmkr:58", "type": "CategoricalVariant", "name": "ESR1 activating variants", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.thGX8CTtcNkncOw3rgSDk0uL1txXvlWk", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_000116.2, the protein product of the MANE Select coding transcript for ESR1 (refseq:NM_000125.4).", "digest": "thGX8CTtcNkncOw3rgSDk0uL1txXvlWk", "sequenceReference": { "id": "ga4gh:SQ.Dcv_jfZMRcmxme6pot93DNwG0ypAfGol", "type": "SequenceReference", "name": "NP_000116.2", "aliases": [ "ensembl:ENSP00000206249.3", "ga4gh:SQ.Dcv_jfZMRcmxme6pot93DNwG0ypAfGol", "refseq:NP_000116.2" ], "description": "The protein product of the MANE Select coding transcript for ESR1 (refseq:NM_000125.4), corresponding to the Refseq protein accession NP_000116.2.", "moleculeType": "protein", "refgetAccession": "SQ.Dcv_jfZMRcmxme6pot93DNwG0ypAfGol", "residueAlphabet": "aa" }, "start": 0, "end": 595, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3467", "conceptType": "Gene", "name": "ESR1", "primaryCoding": { "id": "coding:hgnc:3467", "code": "HGNC:3467", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3467" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000091831", "code": "ENSG00000091831", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000091831" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:2099", "code": "2099", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/2099" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_000125.4", "code": "NM_000125.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_000125.4" ] } } ] } }, { "type": "FunctionConstraint", "functionConsequence": { "id": "func:so:0002053", "name": "Gain-of-function", "primaryCoding": { "id": "coding:so:0002053", "code": "SO:0002053", "name": "gain_of_function_variant", "system": "https://www.ebi.ac.uk/ols4/ontologies/so", "iris": [ "https://www.ebi.ac.uk/ols4/ontologies/so/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FSO_0002053" ] } } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "6" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": null }, { "name": "exon", "value": null }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:orserdu:0", "type": "Indication", "description": "ORSERDU monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2023-09-15:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2023-09-15", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:orserdu", "type": "Document", "documentType": "Regulatory approval", "name": "Orserdu (elacestrant) [product information]. EMA.", "title": null, "aliases": [], "description": "Stemline Therapeutics B.V. Orserdu (elacestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Stemline Therapeutics B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Orserdu", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "elacestrant", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2023-11-27", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-02-14", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }